- Novartis Agrees to Acquire Avidity Biosciences for $12 Billion The Wall Street Journal
- Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash CNBC
- Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion USA Today
- Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis
- Novartis Said to Near $70-Per-Share-Plus Deal for Avidity Bloomberg.com
Source link
